Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on lupus, scleroderma, and Sjogren's

NCT ID NCT06947460

Recruiting now Disease control Sponsor: Beijing GoBroad Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment using a patient's own immune cells, modified to target and attack harmful cells in three severe autoimmune diseases: lupus nephritis, systemic sclerosis, and Sjogren's syndrome with pulmonary hypertension. About 45 adults will receive a single infusion of CD19-BCMA CAR T cells. The main goal is to check safety within the first month, and researchers will also track how well the disease is controlled over the following months. This is an early-phase trial, so the focus is on finding safe doses and watching for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY SJOGREN'S SYNDROME COMBINED WITH PULMONARY HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY SJOGREN'S SYNDROME COMBINED WITH PULMONARY HYPERTENSION REFRACTORY LUPUS NEPHRITIS SYSTEMIC SCLEROSIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • 北京高博医院

    RECRUITING

    Beijing, China,Beijing, 102200, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.